Donald P Bottaro

List of Publications by Year
in descending order

197 papers	15,911 citations	32410 55 h-index	18400 124 g-index
208 all docs	208 docs citations	208 times ranked	17087 citing authors

#	Article	IF	Citations
1	Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. Clinical Cancer Research, 2022, 28, 279-288.	3.2	10
2	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2022, 28, 1353-1362.	3.2	10
3	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	4
4	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. Clinical Cancer Research, 2021, 27, 1391-1398.	3.2	20
5	Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.. Journal of Clinical Oncology, 2021, 39, 3-3.	0.8	7
6	Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs, 2021, 39, 1577-1586.	1.2	3
7	Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS ONE, 2021, 16, e0241766.	1.1	4
8	Clinical Evolution of Epithelialâ€"Mesenchymal Transition in Human Carcinomas. Cancer Research, 2020, 80, 304-318.	0.4	71
9	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. Journal of Clinical Oncology, 2020, 38, 3672-3684.	0.8	78
10	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2020, 21, 1099-1109.	5.1	59
11	Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).. Journal of Clinical Oncology, 2020, 38, 5039-5039.	0.8	2
12	Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.. Journal of Clinical Oncology, 2020, 38, 5037-5037.	0.8	2
13	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	0.9	60
14	Met Signaling in Carcinogenesis. , 2019, , 271-282.		0
15	Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors.. Journal of Clinical Oncology, 2019, 37, 3131-3131.	0.8	1
16	Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).. Journal of Clinical Oncology, 2019, 37, 379-379.	0.8	0
17	Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).. Journal of Clinical Oncology, 2019, 37, 4555-4555.	0.8	0
18	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523

#	Article	IF	Citations
19	Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics, 2018, 17, 698-709.	1.9	9
20	Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS ONE, 2018, 13, e0199361.	1.1	9
21	Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naÃ¯ve (n) or refractory (r) to checkpoint inhibitor (CPI).. Journal of Clinical Oncology, 2018, 36, 4528-4528.	0.8	11
22	Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.. Journal of Clinical Oncology, 2018, 36, 515-515.	0.8	47
23	Abstract A002: Evidence of pazopanib-induced epithelial-mesenchymal transition (EMT) in human tumors. , 2018, , .		0
24	Abstract A127: The identification and development of selective natural product inhibitors of hypoxia inducible factor-2Î± for the treatment of renal cell carcinoma. , 2018, , .		0
25	Abstract 4481: Tumor suppressive role of aquaglyceroporin-3 and PTPN13 in muscle invasive bladder cancer. , 2018, , .		0
26	Hepatocyte growth factor/<scp>MET</scp> in cancer progression and biomarker discovery. Cancer Science, 2017, 108, 296-307.	1.7	190
27	Targeting the hepatocyte growth factor/Met pathway in cancer. Biochemical Society Transactions, 2017, 45, 855-870.	1.6	46
28	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 2405-2413.	3.2	48
29	Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. Annals of Oncology, 2017, 28, v295.	0.6	26
30	A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.. Journal of Clinical Oncology, 2017, 35, 4562-4562.	0.8	16
31	A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.. Journal of Clinical Oncology, 2017, 35, 293-293.	0.8	14
32	Effective implementation of novel MET pharmacodynamic assays in translational studies. Annals of Translational Medicine, 2017, 5, 3-3.	0.7	9
33	Abstract 845: A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics. , 2017, , .		0
34	Abstract 5530: Evidence linking aquaporin-3 loss to increased invasiveness in bladder cancer. , 2017, , .		0
35	MET Inhibition in Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2016, 7, 1205-1214.	1.2	23
36	Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Clinical Cancer Research, 2016, 22, 3683-3694.	3.2	28

#	ARTICLE	IF	CITATIONS
37	A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC). Annals of Oncology, 2016, 27, vi272.	0.6	3
38	A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Annals of Oncology, 2016, 27, vi266.	0.6	10
39	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports, 2016, 14, 2476-2489.	2.9	298
40	The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation. Cellular Signalling, 2016, 28, 1114-1123.	1.7	5
41	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 135-145.	13.9	1,040
42	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2016, 34, 4534-4534.	0.8	8
43	Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells. PLoS ONE, 2016, 11, e0148075.	1.1	4
44	Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. PLoS ONE, 2016, 11, e0157130.	1.1	5
45	Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2553-2553.	0.8	2
46	Abstract 4575: Altered catalytic properties of a subset of Met cytoplasmic domain variants occurring in renal cell carcinoma. , 2016, , .		0
47	MP6-17 PREDICTIVE VALUE OF PLASMA SOLUBLE MET PROTEIN CONCENTRATION IN PATIENTS WITH PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	0
48	Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [^{99m} Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide. Molecular Imaging, 2015, 14, 7290.2015.00023.	0.7	7
49	Expression array analysis of the hepatocyte growth factor invasive program. Clinical and Experimental Metastasis, 2015, 32, 659-676.	1.7	5
50	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma. , 2015, , 303-318.		0
51	Signaling by Met and related receptor tyrosine kinases in urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2015, 33, e15511-e15511.	0.8	0
52	Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group.. Journal of Clinical Oncology, 2015, 33, 4521-4521.	0.8	1
53	Abstract 140: Oncogenic signaling by MET and other cabozantinib targets in cells derived from urothelial carcinoma of the bladder. , 2015, , .		0
54	Abstract 5082: Impact of HGF knockin microenvironment on epithelial-mesenchymal transition and cancer stem cells in a non-small cell lung cancer xenograft model. , 2015, , .		2

#	Article	IF	Citations
55	Abstract LB-B18: Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy. , 2015, , .		0
56	Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide. Molecular Imaging, 2015, 14, 499-515.	0.7	4
57	Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. PLoS ONE, 2014, 9, e100586.	1.1	52
58	Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine, 2014, 12, 199.	1.8	14
59	Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. Cancers, 2014, 6, 2313-2329.	1.7	14
60	537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. European Journal of Cancer, 2014, 50, 175.	1.3	0
61	Synergistic Signaling of Tumor Cell Invasiveness by Hepatocyte Growth Factor and Hypoxia. Journal of Biological Chemistry, 2014, 289, 20448-20461.	1.6	26
62	Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist. Leukemia, 2014, 28, 948-951.	3.3	6
63	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475.	1.9	227
64	Abstract 3691: Met target inhibition-guided efficacy in preclinical models. , 2014, , .		1
65	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2014, 32, 4501-4501.	0.8	28
66	Quantification of MET expression using mass spectrometry (MS): Assay precision and stability in FFPE tumor tissue.. Journal of Clinical Oncology, 2014, 32, 16-16.	0.8	1
67	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2014, 32, 307-307.	0.8	6
68	Met signaling in urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2014, 32, 4551-4551.	0.8	0
69	Abstract 1049: Quantitative immunofluorescence assessment of MET and epithelial to mesenchymal transition (EMT) biomarker modulation by antiangiogenic inhibitors in xenograft tumor tissues. , 2014, , .		0
70	Abstract 4670: Characterization of Met signaling in urothelial cancer of the bladder. , 2014, , .		0
71	Abstract 5259: Gene expression array and pathway profiling analyses distinguish HGF/Met pathways driving cell proliferation from invasion and identify events correlated with prostate cancer progression. , 2014, , .		0
72	Abstract 489: Hypoxia-mediated ROS enhances HGF-induced cancer cell invasion and suppresses cell cycle progression. , 2014, , .		0

#	Article	IF	Citations
73	Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, 181-186.	0.8	401
74	Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE, 2013, 8, e54014.	1.1	174
75	Isolation and Identification of Natural Products from Artocarpus communis. Planta Medica, 2013, 79, .	0.7	1
76	A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2013, 31, TPS4589-TPS4589.	0.8	3
77	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 314-314.	0.8	6
78	Abstract 4085: Experimental metastasis by the prostate adenocarcinoma-derived cell line PC3M is driven by partial activation of the human Met pathway.. , 2013, , .		0
79	Abstract 5637: A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma.. , 2013, , .		0
80	Abstract 4285: Hypoxia-mediated autophagy enhances HGF-induced cancer cell invasion.. , 2013, , .		0
81	Developing a molecular imaging agent for Met using onartuzumab (MetMAb).. Journal of Clinical Oncology, 2013, 31, 11083-11083.	0.8	0
82	Application of MET pharmacodynamic assays to compare effectiveness of five MET inhibitors to engage target in tumor tissue.. Journal of Clinical Oncology, 2013, 31, 11103-11103.	0.8	1
83	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 4543-4543.	0.8	1
84	Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 553-572.	1.5	197
85	Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab. Journal of Nuclear Medicine, 2012, 53, 1592-1600.	2.8	54
86	Targeted Disruption of Heparan Sulfate Interaction with Hepatocyte and Vascular Endothelial Growth Factors Blocks Normal and Oncogenic Signaling. Cancer Cell, 2012, 22, 250-262.	7.7	44
87	448 CHARACTERIZATION OF THE AKT-MTOR PATHWAY IN TFE3-FUSION RENAL CELL CANCERS AND IMPLICATIONS FOR TARGETED THERAPY. Journal of Urology, 2012, 187, .	0.2	2
88	1283 URINARY MET LEVEL AS A NOVEL BIOMARKER FOR UROTHELIAL CARCINOMA OF THE BLADDER. Journal of Urology, 2012, 187, .	0.2	0
89	Inhibition of Hypoxia Inducible Factor-2 Transcription: Isolation of Active Modulators from Marine Sponges. Journal of Natural Products, 2012, 75, 1632-1636.	1.5	15
90	A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.. Journal of Clinical Oncology, 2012, 30, 355-355.	0.8	8

#	Article	IF	Citations
91	Correlation of germline <i>MET</i> mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).. Journal of Clinical Oncology, 2012, 30, 372-372.	0.8	37
92	Heparin Inhibits Hepatocyte Growth Factor Induced Motility and Invasion of Hepatocellular Carcinoma Cells through Early Growth Response Protein 1. PLoS ONE, 2012, 7, e42717.	1.1	43
93	Novel Antagonists of Heparin Binding Growth Factors. Oncotarget, 2012, 3, 911-912.	0.8	1
94	Abstract 1225: Integration of HGF/Met signaling and hypoxia response in cancer cell invasion and proliferation. , 2012, , .		0
95	A New Hypoxia Inducible Factor-2 Inhibitory Pyrrolinone Alkaloid from Roots and Stems of Piper sarmentosum. Chemical and Pharmaceutical Bulletin, 2011, 59, 1178-1179.	0.6	32
96	Application of ringâ€closing metathesis to Grb2 SH3 domainâ€binding peptides. Biopolymers, 2011, 96, 780-788.	1.2	10
97	Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2Î± induced gene expression. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2113-2115.	1.0	23
98	Development and validation of biomarker assays to assess pharmacodynamic modulation of MET.. Journal of Clinical Oncology, 2011, 29, 3042-3042.	0.8	4
99	The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. Current Signal Transduction Therapy, 2011, 6, 146-151.	0.3	26
100	Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2011, 29, 257-257.	0.8	21
101	Use of a MET-specific photoprobe to identify bladder tumors in an orthotopic xenograft model of bladder cancer.. Journal of Clinical Oncology, 2011, 29, 260-260.	0.8	0
102	A hepatocyte growth factor antagonist engineered by site-directed mutagenesis.. Journal of Clinical Oncology, 2011, 29, 10528-10528.	0.8	0
103	Abstract A204: A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma.. , 2011, , .		0
104	Gab1 mediates hepatocyte growth factorâ€stimulated mitogenicity and morphogenesis in multipotent myeloid cells. Journal of Cellular Biochemistry, 2010, 111, 310-321.	1.2	14
105	A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2010, 299, L905-L914.	1.3	9
106	Molecular Diagnosis and Therapy of Kidney Cancer. Annual Review of Medicine, 2010, 61, 329-343.	5.0	154
107	Targeting the HGF/Met signalling pathway in cancer. European Journal of Cancer, 2010, 46, 1260-1270.	1.3	180
108	Abstract 342: A hepatocyte growth factor antagonist engineered by disruption of heparan sulfate binding. , 2010, , .		0

#	Article	IF	Citations
109	Abstract 3401: Genetic down-regulation of MET alters the metastatic phenotype of osteosarcoma cells. , 2010, , .		0
110	Abstract 773: Identification and characterization of natural product-based inhibitors of hypoxia inducible factor-2 alpha. , 2010, , .		0
111	Targeting the Met signaling pathway in renal cancer. Expert Review of Anticancer Therapy, 2009, 9, 785-793.	1.1	66
112	Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer. Clinical Cancer Research, 2009, 15, 4292-4298.	3.2	45
113	Hereditary kidney cancer. Cancer, 2009, 115, 2252-2261.	2.0	101
114	Identification of Shc Src Homology 2 Domain-Binding Peptoidâ˘Peptide Hybrids. Journal of Medicinal Chemistry, 2009, 52, 1612-1618.	2.9	10
115	VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. International Journal of Biochemistry and Cell Biology, 2009, 41, 753-756.	1.2	49
116	Directed Discovery of Agents Targeting the Met Tyrosine Kinase Domain by Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 943-951.	2.9	56
117	Abstract A8: Final results of a phase I dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to patients with solid tumors. , 2009, , .		3
118	Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients. , 2009, , .		2
119	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma. , 2009, , 321-334.		0
120	Abstract A163: Development of Grb2 SH3 domain antagonists. , 2009, , .		0
121	Abstract B228: A hepatocyte growth factor antagonist engineered by targeted disruption of heparan sulfate binding. , 2009, , .		0
122	Urinary c-Met Levels as an Indicator of Disease Progression in Glioblastoma Multiforme Patients. International Journal of Radiation Oncology Biology Physics, 2008, 72, S215.	0.4	0
123	Urinary c-Met, a Novel Biomarker of Metastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, S57-S58.	0.4	0
124	Von Hippel-Lindau Tumor Suppressor Gene Loss in Renal Cell Carcinoma Promotes Oncogenic Epidermal Growth Factor Receptor Signaling via Akt-1 and MEK-1. European Urology, 2008, 54, 845-854.	0.9	14
125	Grb2 signaling in cell motility and cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 1021-1033.	1.5	162
126	Selectivity and Mechanism of Action of a Growth Factor Receptor-Bound Protein 2 Src Homology 2 Domain Binding Antagonist. Journal of Medicinal Chemistry, 2008, 51, 7459-7468.	2.9	10

#	Article	IF	Citations
127	Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2. , 2008, , 181-191.		0
128	Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics. Clinical Cancer Research, 2007, 13, 671s-679s.	3.2	131
129	Inhibition of Tumor Metastasis by a Growth Factor Receptor Bound Protein 2 Src Homology 2 Domainâ€"Binding Antagonist. Cancer Research, 2007, 67, 6012-6016.	0.4	41
130	Loss of Secreted Frizzled-Related Protein-1 Expression in Renal Cell Carcinoma Reveals a Critical Tumor Suppressor Function. Clinical Cancer Research, 2007, 13, 4660-4663.	3.2	6
131	Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis. Organic and Biomolecular Chemistry, 2007, 5, 367-372.	1.5	10
132	Synthesis and Use of C-terminally Biotinylated Peptidomimetics with High Grb2 SH2 Domain-binding Affinity. , 2006, , 208-209.		0
133	Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anti-Cancer Drugs, 2006, 17, 13-20.	0.7	65
134	Beta Catenin Signaling: Linking Renal Cell Carcinoma and Polycystic Kidney Disease. Cell Cycle, 2006, 5, 2839-2841.	1.3	17
135	c-Met Ectodomain Shedding Rate Correlates with Malignant Potential. Clinical Cancer Research, 2006, 12, 4154-4162.	3.2	76
136	Targeting the c-Met Signaling Pathway in Cancer: Fig. 1.. Clinical Cancer Research, 2006, 12, 3657-3660.	3.2	414
137	The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14531-14536.	3.3	102
138	Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1385-1388.	1.0	13
139	Multifocal Renal Cancer: Genetic Basis and Its Medical Relevance. Clinical Cancer Research, 2005, 11, 7206-7208.	3.2	12
140	Examination of Phosphoryl-Mimicking Functionalities within a Macrocyclic Grb2 SH2 Domain-Binding Platform. Journal of Medicinal Chemistry, 2005, 48, 3945-3948.	2.9	24
141	Hereditary Papillary Renal Carcinoma Type I. Current Molecular Medicine, 2004, 4, 855-868.	0.6	89
142	0.2 T magnetic field inhibits angiogenesis in chick embryo chorioallantoic membrane. Bioelectromagnetics, 2004, 25, 390-396.	0.9	41
143	Genetic Basis of Cancer of the Kidney. Clinical Cancer Research, 2004, 10, 6282S-6289S.	3.2	187
144	Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. Molecular Cancer Therapeutics, 2004, 3, 1289-99.	1.9	24

#	ARTICLE	IF	CITATIONS
145	Out of air is not out of action. Nature, 2003, 423, 593-595.	13.7	158
146	Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinaseâ€3Î². FASEB Journal, 2002, 16, 950-962.	0.2	159
147	Direct Application of Keratinocyte Growth Factor, Basic Fibroblast Growth Factor and Transforming Growth Factor-Î± During Healing of Tympanic Membrane Perforation in Glucocorticoid-treated Rats. Acta Oto-Laryngologica, 2002, 122, 468-473.	0.3	23
148	Regulation of leukemic cell adhesion, proliferation, and survival by Î²-catenin. Blood, 2002, 100, 982-990.	0.6	125
149	Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. Oncogene, 2002, 21, 2201-2211.	2.6	9
150	Molecular Signaling in Bioengineered Tissue Microenvironments. Annals of the New York Academy of Sciences, 2002, 961, 143-153.	1.8	85
151	The Role of Extracellular Matrix Heparan Sulfate Glycosaminoglycan in the Activation of Growth Factor Signaling Pathways. Annals of the New York Academy of Sciences, 2002, 961, 158-158.	1.8	5
152	Title is missing!. Biotechnology Letters, 2002, 24, 1631-1635.	1.1	6
153	Engineered Extracellular Matrices: A Biological Solution for Tissue Repair, Regeneration, and Replacement. , 2001, 2, 9-12.		2
154	Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: Involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade. Arthritis and Rheumatism, 2001, 44, 73-84.	6.7	46
155	Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions. Journal of Biological Chemistry, 2001, 276, 14308-14314.	1.6	87
156	Dissociation of Heparan Sulfate and Receptor Binding Domains of Hepatocyte Growth Factor Reveals That Heparan Sulfate-c-Met Interaction Facilitates Signaling. Journal of Biological Chemistry, 2001, 276, 32977-32983.	1.6	93
157	Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors. Oncogene, 2000, 19, 640-648.	2.6	29
158	Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases. Oncogene, 2000, 19, 2846-2854.	2.6	29
159	Disassociation of Met-Mediated Biological Responses In Vivo: the Natural Hepatocyte Growth Factor/Scatter Factor Splice Variant NK2 Antagonizes Growth but Facilitates Metastasis. Molecular and Cellular Biology, 2000, 20, 2055-2065.	1.1	56
160	Secreted Frizzled-related Protein-1 Binds Directly to Wingless and Is a Biphasic Modulator of Wnt Signaling. Journal of Biological Chemistry, 2000, 275, 4374-4382.	1.6	338
161	A cell-permeable peptide inhibits activation of PKR and enhances cell proliferation. Peptides, 2000, 21, 1449-1456.	1.2	25
162	Isolation and Biochemical Characterization of the Human Dkk-1 Homologue, a Novel Inhibitor of Mammalian Wnt Signaling. Journal of Biological Chemistry, 1999, 274, 19465-19472.	1.6	241

#	Article	IF	Citations
163	Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene, 1999, 18, 3399-3406.	2.6	80
164	Identification and Dynamics of a Heparin-Binding Site in Hepatocyte Growth Factorâ€. Biochemistry, 1999, 38, 14793-14802.	1.2	57
165	Heparan Sulfate Proteoglycan Modulates Keratinocyte Growth Factor Signaling through Interaction with both Ligand and Receptor. Biochemistry, 1999, 38, 1765-1771.	1.2	45
166	The Acidic Domain and First Immunoglobulin-Like Loop of Fibroblast Growth Factor Receptor 2 Modulate Downstream Signaling through Glycosaminoglycan Modification. Molecular and Cellular Biology, 1999, 19, 6754-6764.	1.1	14
167	Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor. Oncogene, 1998, 17, 481-492.	2.6	25
168	The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site. Structure, 1998, 6, 109-116.	1.6	61
169	Smad2 transduces common signals from receptor serineâ€“threonine and tyrosineâ€‰kinases. Genes and Development, 1998, 12, 1587-1592.	2.7	262
170	Colocalization of Heparin and Receptor Binding Sites on Keratinocyte Growth Factorâ€. Biochemistry, 1998, 37, 8853-8862.	1.2	16
171	Identification of Serine 643 of Protein Kinase C-Î´ as an Important Autophosphorylation Site for Its Enzymatic Activity. Journal of Biological Chemistry, 1997, 272, 24550-24555.	1.6	68
172	Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in <i>Escherichia coli</i>. Biochemical Journal, 1997, 326, 763-772.	1.7	52
173	A novel human ERK phosphatase regulates H-ras and v-raf signal transduction. Oncogene, 1997, 14, 2633-2639.	2.6	42
174	Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. EMBO Journal, 1997, 16, 5608-5617.	3.5	114
175	Peptides Derived from the Interferon-Induced PKR Prevent Activation by HIV-1 TAR RNA. Virology, 1996, 222, 193-200.	1.1	15
176	Microtubule dynamic turnover is suppressed during polarization and stimulated in hepatocyte growth factor scattered Madin-Darby canine kidney epithelial cells. , 1996, 35, 225-236.		17
177	Identification of Tyrosine 187 as a Protein Kinase C-Î´ Phosphorylation Site. Journal of Biological Chemistry, 1996, 271, 26404-26409.	1.6	58
178	Hepatocyte Growth Factor (HGF)/NK1 Is a Naturally Occurring HGF/Scatter Factor Variant with Partial Agonist/Antagonist Activity. Journal of Biological Chemistry, 1996, 271, 13110-13115.	1.6	123
179	Keratinocyte growth factor. Cell Biology International, 1995, 19, 399-412.	1.4	261
180	Human Dual Specificity Phosphatase VHR Activates Maturation Promotion Factor and Triggers Meiotic Maturation in Xenopus Oocytes. Journal of Biological Chemistry, 1995, 270, 14229-14234.	1.6	17

#	Article	IF	Citations
181	Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science, 1995, 267, 381-383.	6.0	853
182	High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 989-993.	3.3	72
183	Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7144-7148.	3.3	116
184	Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochimica Et Biophysica Acta: Reviews on Cancer, 1993, 1155, 357-371.	3.3	135
185	Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 246-250.	3.3	729
186	Expression cloning of a human dual-specificity phosphatase.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 12170-12174.	3.3	199
187	Keratinocyte Growth Factor: A Fibroblast Growth Factor Family Member with Unusual Target Cell Specificity. Annals of the New York Academy of Sciences, 1991, 638, 62-77.	1.8	138
188	A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 415-419.	3.3	504
189	Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science, 1991, 251, 72-75.	6.0	430
190	Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science, 1991, 251, 802-804.	6.0	2,206
191	Identification of a competitive HGF antagonist encoded by an alternative transcript. Science, 1991, 254, 1382-1385.	6.0	223
192	PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature, 1989, 342, 711-714.	13.7	502
193	The 18 kDa cytosolic acid phosphatase from bovine liver has phosphotyrosine phosphatase activity on the autophosphorylated epidermal growth factor receptor. FEBS Letters, 1989, 250, 469-473.	1.3	84
194	The American microcirculatory society landis award lecture. Microvascular Research, 1988, 35, ii-264.	1.1	18
195	Heterogeneity of intimal and microvessel endothelial cell barriers in vitro. Microvascular Research, 1986, 32, 389-398.	1.1	44
196	Serotonin, norepinephrine, and histamine mediation of endothelial cell barrier function in vitro. Journal of Cellular Physiology, 1986, 128, 189-194.	2.0	69
197	Hepatocyte growth factor/Met signaling in cancer. , 0, , 204-217.		1